Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99m Tc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial
Journal of Nuclear Medicine · 2026-06 · 67 (6) · 895-902
DOI: 10.2967/jnumed.125.270347 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 26.03.2026. Verfasst von Alicja Hubalewska-Dydejczyk und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland. Hauptthemen laut MEDLINE: Receptors, Somatostatin, Neuroendocrine Tumors, Organotechnetium Compounds. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Visual Abstract Neuroendocrine neoplasms (NENs) are a heterogeneous group of neoplasms in which an adequate expression of a somatostatin receptor (SSTR) serves as a target for imaging and therapy, typically using SSTR agonists. In the past decade, research in the field of NENs has focused on SSTR antagonists because of their higher and more sustained binding to a target, which may expand current diagnostic and therapeutic options, especially in patients with lower SSTR expression. The aim of this study was to perform a first-in-human injection of a novel 99mTc-labeled SSTR type 2 antagonist to establish safety, pharmacokinetics, and first assessment of SSTR status in patients with NENs through a qualitative and quantitative comparison with 68Ga-SSTR PET as a reference standard.
Methods
Patients with metastatic grade 1 or 2 NENs and proven SSTR expression in primary and metastatic lesions on SSTR PET were imaged after a first-in-human injection of [99mTc]Tc-TECANT1. Assessment of safety, pharmacokinetics, and dosimetry was performed as a primary endpoint, with comparison of diagnostic performance and quantification of uptake to SSTR PET as a secondary endpoint.
Results
Ten patients were enrolled. [99mTc]Tc-TECANT1 was found to be safe, with favorable pharmacokinetics and dosimetry (average total body effective dose of 3.3 ± 0.7 mSv). The diagnostic performance in comparison to that of SSTR PET was found to be superior, with a comparable or a higher number of detected lesions and superior target-to-background contrast (a factor of 2 and above for lesions with the highest uptake). Conclusion: [99mTc]Tc-TECANT1 appears to be a safe and widely utilizable radiopharmaceutical for the assessment of SSTR expression status in NENs. Validation of results in a larger cohort is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland.
- Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
- Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland.
- Division of Nuclear Medicine, University Medical Centre Ljubljana, University of Ljubljana, Ljubljana, Slovenia.
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
- Department of Biophysics, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Zitieren
APA
Hubalewska-Dydejczyk, A., Decristoforo, C., Mikolajczak, R., Kolenc, P., Opalinska, M., Garnuszek, P., Skorkiewicz, K., Glowa, B., Trofimiuk-Muldner, M., Studen, A., Simoncic, U., Rangger, C., di Santo, G., Fani, M., Virgolini, I., & Lezaic, L. (2026). Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99m Tc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial. Journal of Nuclear Medicine, 67(6), 895-902. https://doi.org/10.2967/jnumed.125.270347
Vancouver
Hubalewska-Dydejczyk A, Decristoforo C, Mikolajczak R, Kolenc P, Opalinska M, Garnuszek P, et al. Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99m Tc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial. Journal of Nuclear Medicine. 2026;67(6):895-902. doi:10.2967/jnumed.125.270347
BibTeX
@article{HubalewskaDydejczyk2026,
author = {Hubalewska-Dydejczyk, Alicja and Decristoforo, Clemens and Mikolajczak, Renata and Kolenc, Petra and Opalinska, Marta and Garnuszek, Piotr and Skorkiewicz, Konrad and Glowa, Bogusław and Trofimiuk-Muldner, Malgorzata and Studen, Andrej and Simoncic, Urban and Rangger, Christine and di Santo, Gianpaolo and Fani, Melpomeni and Virgolini, Irene and Lezaic, Luka},
title = {Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99m Tc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {6},
pages = {895--902},
doi = {10.2967/jnumed.125.270347}
}
EUVIMED